aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
5.15
-0.08 (-1.53%)
Aug 13, 2025, 4:00 PM - Market closed
United States Steel Revenue
In the year 2024, aTyr Pharma had annual revenue of $235.00K, down -33.43%.
Revenue (ttm)
$235.00K
Revenue Growth
-33.43%
P/S Ratio
n/a
Revenue / Employee
$3,615
Employees
65
Market Cap
504.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 235.00K | -118.00K | -33.43% |
| Dec 31, 2023 | 353.00K | -10.03M | -96.60% |
| Dec 31, 2022 | 10.39M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 10.46M | 10.03M | 2,377.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ATYR News
- 6 days ago - aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update - GlobeNewsWire
- 14 days ago - Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors - GlobeNewsWire
- 22 days ago - aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis - GlobeNewsWire
- 6 weeks ago - aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes - GlobeNewsWire
- 2 months ago - aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) - GlobeNewsWire
- 3 months ago - aTyr Pharma to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference - GlobeNewsWire
- 3 months ago - aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire